Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,245,668 papers from all fields of science
Search
Sign In
Create Free Account
Mitoxantrone
Known as:
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthroquinone
, 1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
, Mitoxantronum
Expand
An anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
49 relations
Broader (2)
Antineoplastic Agents
anthracene
Narrower (26)
BBR 2577
BBR3378
CL 232315
DMV regimen
Expand
Congestive heart failure
In Blood
Mammary Neoplasms
Mitoxantrone Hydrochloride
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
J. Bono
,
S. Oudard
,
+10 authors
A. Sartor
The Lancet
2010
Corpus ID: 4791847
Review
2010
Review
2010
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Y. Pommier
,
Elisabetta Leo
,
Hongliang Zhang
,
C. Marchand
Chemistry & biology
2010
Corpus ID: 40526592
Highly Cited
2008
Highly Cited
2008
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
D. Berthold
,
G. Pond
,
F. Soban
,
R. de Wit
,
M. Eisenberger
,
I. Tannock
Journal of clinical oncology : official journal…
2008
Corpus ID: 17253389
PURPOSE The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each…
Expand
Highly Cited
2004
Highly Cited
2004
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
I. Tannock
,
R. de Wit
,
+9 authors
M. Eisenberger
The New England journal of medicine
2004
Corpus ID: 22649502
BACKGROUND Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory…
Expand
Highly Cited
2004
Highly Cited
2004
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
D. Petrylak
,
C. Tangen
,
+11 authors
E. Crawford
The New England journal of medicine
2004
Corpus ID: 2779676
BACKGROUND Mitoxantrone-based chemotherapy palliates pain without extending survival in men with progressive androgen-independent…
Expand
Highly Cited
2002
Highly Cited
2002
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial
H. Hartung
,
R. Gonsette
,
+5 authors
T. Zwingers
The Lancet
2002
Corpus ID: 2437130
Highly Cited
1999
Highly Cited
1999
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.
K. Miyake
,
L. Mickley
,
+8 authors
S. Bates
Cancer research
1999
Corpus ID: 1524156
Reports of multiple distinct mitoxantrone-resistant sublines without overexpression of P-glycoprotein or the multidrug-resistance…
Expand
Highly Cited
1999
Highly Cited
1999
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
P. Kantoff
,
S. Halabi
,
+6 authors
N. Vogelzang
Journal of clinical oncology : official journal…
1999
Corpus ID: 36557343
PURPOSE Approximately 40,000 men die each year of hormone-refractory prostate cancer (HRPC). The results of treatment with…
Expand
Highly Cited
1998
Highly Cited
1998
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study.
B. Coiffier
,
C. Haioun
,
+10 authors
F. Reyes
Blood
1998
Corpus ID: 7284595
Rituximab, a chimeric monoclonal antibody that binds specifically to the CD20 antigen, induced objective responses in 50% of…
Expand
Highly Cited
1996
Highly Cited
1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
I. Tannock
,
D. Osoba
,
+8 authors
K. Murphy
Journal of clinical oncology : official journal…
1996
Corpus ID: 395768
PURPOSE To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE